HitGen
68822228.264.72% ( -1.40 )
HitGen (688222)
HitGen Inc. operates as a drug discovery research platform for small molecules and nucleic acid drugs in China and internationally. Its technology platform incl...
- Open
- 29.50
- High
- 29.78
- Low
- 28.00
- Prev. Close
- 29.66
- Volume
- 138.44K
- Turnover
- 396.81M
- Avg Price
- 28.66
- Bid/Ask Ratio
- --
- Amplitude
- 6.00%
- 52wk High
- 42.85
- Volume Ratio
- 0.51
- Turnover Ratio
- 3.46%
HitGen Analyst Rating
View MoreForecast & Rating
May 26, 2026Price forecast
¥31.6011.82%
Forecast & RatingStrong buy
4analysts
- Strong buy75.00%
- Buy25.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PR Newswire · Jul 14 at 03:30 AM
HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction
- prnewswire · Apr 29 at 06:02 AM
07:00 ETESG | HitGen Releases 2025 Sustainability Report
- 36Kr · Jan 10 at 07:31 PM
Post-holiday institutional research stocks exposed
- StockTitan · Sep 15, 2025 at 08:30 AM
HitGen Partner BioAge Labs Initiates Phase 1 Clinical Study of BGE-102, a Novel Brain-Penetrant NLRP3 inhibitor | BIOA Stock News
- Zhitong · Sep 14, 2025 at 08:12 PM
HitGen: Partner BioAge launches Phase I clinical study of novel NLRP3 inhibitor BGE-102
- Zhitong · Sep 9, 2025 at 01:19 AM
A-share innovative drug concept stocks fluctuated lower, with InventisBio falling over 10%. Other stocks such as Huahai Pharmaceutical, JENKEM, Lifeon Pharmaceutical, JOINN, Guangsheng Tang, HitGen, and Baillie Gifford also dropped more than 6%
